4[4]MONTELEONE G,MACDONALD T T.Manipulation of cytokines in the management of patients with inflammatory bowel disease[J].Ann Med,2000,32(8):552-560.
5[5]ANAND A C,ADYA C M.Cytokines and inflammatory bowel disease[J].Trop Gastroenterol,1999,20(3):97-106.
6[6]CAROL M,LAMBRECHTS A,van COSSUM A,et al.Spontaneous secretion of interferon γ and interleukin 4 by human intraepithelial and lamina propria gut lymphocytes[J].GUT,1998,42(5):643-649.
7[7]FORT M,LESLEY R,DAVIDSON N,et al .IL-4 exacerbates disease in a Th1 cell transfer model of colitis[J].J Immunol,2001,166(4):2793-2800.
8[8]CAMOGLIO L,te VELDE A A,TIGGES A J,et al .Altered expression of interferon-gamma and interleukin-4 in inflammatory bowel disease[J].Inflamm Bowel Dis,1998,4(4):285-290.
2Ikeda Y, Akbar SM, Matsui H, Onji M. Antigen-presenting dendritic cells in ulcerative colitis. J Gastroenterol 2002;37(Suppl 14):53-55.
3Bamias G, Marini M, Moskaluk CA, Odashima M, Ross WG,Rivera-Nieves J, Cominelli F. Down-regulation of intestinal lymphocyte activation and Thl cytokine production by antibiotic therapy in a murine model of Crohn's disease. J Immunol 2002;169:5308-5314.
4Sawa Y, Oshitani N, Adachi K, Higuchi K, Matsumoto T,Arakawa T. Comprehensive analysis of intestinal cytokine messenger RNA profile by real-time quantitative polymerase chain reaction in patients with inflammatory bowel disease.Int J Mol Med 2003;11:175-179.
5Lakatos L. Immunology of inflammatory bowel diseases. Acta Physiol Hung 2000;87:355-372.
6Hata K, Andoh A, Sato H, Araki Y, Tanaka M, Tsujikawa T,Fujiyama Y, Bamba T. Sequential changes in luminal microflora and mucosal cytokine expression during developing of colitis in HLA-B27/beta2-microglobulin transgenic rats. Scand J Gastroenterol 2001;36:1185-1192.
7Sun FF, Lai PS, Yue G, Yin K, Nagele RG, Tong DM, Krzesicki RF, Chin JE, Wong PY. Pattern of cytokine and adhesion molecule mRNA in hapten- induced relapsing colon inflammation in the rat. Inflammation 2001;25:33-45.
8Sandborn WJ. Strategies for targeting tumour necrosis factor in IBD. Best Pract Res Clin Gastroenterol 2003;17:105-117.
9Su C, Salzberg BA, Lewis JD, Deren JJ, Kornbluth A, Katzka DA, Stein RB, Adler DR, Lichtenstein GR. Efficacy of antitumor necrosis factor therapy in patients with ulcerative colitis.Am J Gastroenterol 2002;97:2577-2584.
10Garrelds IM, Heiligers JP, Van Meeteren ME, Duncker DJ,Saxena PR, Meijssen MA, Zijlstra FJ.Interleukin-2-Deficient mice: effect on cytokines and inflammatory cells in chronic colonic disease. Dig Dis Sci 2002;47:503-510.
8DAMME NV, KEYSER FD, DEMETTER P, et al. The proportion of Thl cells, which prevail in gut mucosa, is decreased in inflammatory bowel syndrome [ J ]. Clin Exp Immunol, 2001,125 (3) :383 - 390.
9MACDONALD TT, MONTELEONE G, PENDER SL. Recent development in the immunology inflammatory bowel disease[ J]. Scand Immunol, 2000,51 ( 1 ) :2 - 9.
